UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Journal of clinical oncology, 2006-12, Vol.24 (34), p.5343-5349

2006

Volltextzugriff (PDF)

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood, 2021-09, Vol.138 (9), p.811-814

2021

Volltextzugriff (PDF)

Efficacy and safety of examethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) lymphoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e19023-e19023

2016

Volltextzugriff (PDF)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

Blood advances, 2023-04, Vol.7 (7), p.1146-1155

2023

Volltextzugriff (PDF)

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)

Blood, 2005-11, Vol.106 (10), p.3348-3352

2005

Volltextzugriff (PDF)

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial

Leukemia & lymphoma, 2009-01, Vol.50 (7), p.1096-1101

2009

Volltextzugriff (PDF)

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma

Seminars in oncology, 2002-02, Vol.29 (1), p.36-40

2002

Volltextzugriff (PDF)

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

Blood, 2008-11, Vol.112 (11), p.2726-2726

2008

Volltextzugriff (PDF)

International Staging System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myeloma (MM)

Blood, 2008-11, Vol.112 (11), p.2745-2745

2008

Volltextzugriff (PDF)

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity

Blood, 2007-11, Vol.110 (11), p.1369-1369

2007

Volltextzugriff (PDF)

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma

Seminars in oncology, 2002-02, Vol.29 (1S2), p.36

2002

Volltextzugriff (PDF)

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma

Blood, 2007-11, Vol.110 (11), p.4844-4844

2007

Volltextzugriff (PDF)

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2007-11, Vol.110 (11), p.4433-4433

2007

Volltextzugriff (PDF)

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation

Blood, 2007-11, Vol.110 (11), p.5130-5130

2007

Volltextzugriff (PDF)

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results

Blood, 2004-11, Vol.104 (11), p.1396-1396

2004

Volltextzugriff (PDF)

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial

Blood, 2004-11, Vol.104 (11), p.3476-3476

2004

Volltextzugriff (PDF)

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial

Blood, 2004-11, Vol.104 (11), p.3476-3476

2004

Volltextzugriff (PDF)

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM)

Blood, 2004-11, Vol.104 (11), p.3463-3463

2004

Volltextzugriff (PDF)

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma: Current and ongoing clinical development of immunotherapy in B-cell malignancies

Seminars in oncology, 2002, Vol.29 (1), p.36-40

2002

Volltextzugriff (PDF)

Adolescent substance-abuse: Vulnerability and protective factors from a developmental perspective

Mohr, Alice F

1998

Volltextzugriff (PDF)

"David Caplovitz:" CONSUMERS IN TROUBLE (Book Review)

Social Forces, 1976, Vol.54 (3), p.723-723

Mohr, Alice W

1976

Volltextzugriff (PDF)

Looking at Metacognitive Learning Strategies Using a Developmental Lens

2000

Volltextzugriff (PDF)

Consumers in Trouble: A Study of Debtors in Default

Social Forces, 1976, Vol.54 (3), p.723-724

Mohr, Alice W.

1976

Volltextzugriff (PDF)

Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis

The New England journal of medicine, 2010-07, Vol.363 (1), p.11-23

2010

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(49)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(25)
Humans
(16)
Female
(7)
Adult
(6)
Animals
(6)
Male
(6)
Middle Aged
(6)
Aged
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Oncology
(5)
Chemotherapy
(4)
Hematology
(4)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Mice
(3)
Neurosciences
(3)
Pharmacology & Pharmacy
(3)
Pharmacology. Drug Treatments
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

Efficacy and safety of examethasone, high dose cytarabine, and carboplatin (DHAC) with and without rituximab (R) as a salvage regimen for relapsed/refractory (R/R) lymphoma

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

International Staging System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myeloma (MM)

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM)

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma: Current and ongoing clinical development of immunotherapy in B-cell malignancies

Adolescent substance-abuse: Vulnerability and protective factors from a developmental perspective

"David Caplovitz:" CONSUMERS IN TROUBLE (Book Review)

Looking at Metacognitive Learning Strategies Using a Developmental Lens

Consumers in Trouble: A Study of Debtors in Default

Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis

Suchergebnisse filtern